Nitrogen Containing Reactant Patents (Class 530/409)
-
Publication number: 20100330161Abstract: Orally active vitamin B12-tetanus toxoid (TT) conjugates are described. Attachment of TT to vitamin B12 provides for uptake of the conjugate from the digestive tract, and allows for delivery of the immunologically active TT to the blood. Pharmaceutical compositions and methods of disease prevention employing the orally active Vitamin B12-TT conjugate of the invention are also described.Type: ApplicationFiled: June 29, 2010Publication date: December 30, 2010Applicant: SYRACUSE UNIVERSITY TECHNOLOGY TRANSFER AND INDUSTRIAL DEVELOPMENT OFFICEInventors: Robert Patrick Doyle, Anthony Vortherms
-
Publication number: 20100323421Abstract: It is an object of the present invention to provide a method for chemically modifying biopolymer and polypeptide with a hydrophobic compound or a compound which causes degradation or reaction under basic condition. The present invention provides a method for producing a chemically modified biopolymer or polypeptide, wherein a biopolymer or polypeptide is chemically modified in a reaction solution containing an organic fluorine compound.Type: ApplicationFiled: November 28, 2008Publication date: December 23, 2010Applicant: FUJIFILM CorporationInventors: Shouji Ooya, Tetsuo Hiratou, Kentaro Nakamura
-
Publication number: 20100324266Abstract: Novel compounds are provided, which are useful as linking groups in chemical synthesis, preferably in the solid phase synthesis of oligonucleotides and polypeptides. These compounds are generally photolabile and comprise protecting groups which can be removed by photolysis to unmask a reactive group. The protecting group has the general formula Y, wherein Y is a chemical structure as shown in FIG. 1. Also provided is a method of forming, from component molecules, a plurality of compounds on a support, each compound occupying a separate predefined region of the support, using the protected compounds described above.Type: ApplicationFiled: June 9, 2010Publication date: December 23, 2010Applicant: Affymetrix, INC.Inventors: Anthony D. Barone, Glenn H. McGall
-
Publication number: 20100322958Abstract: Modified capsular saccharides comprising a blocking group at a hydroxyl group position on at least one of the monosaccharide units of the corresponding native capsular saccharide, wherein the blocking group is of the formula (Ia) or (Ib): —OX—Y (Ia) or —O—R1 (Ib) wherein X is C(O), S(O) or SO2; Y is NR1R2 or R3; R1 is C1-6 alkyl substituted with 1, 2 or 3 groups independently selected from hydroxyl, sulphydryl and amine; R2 is H or C1-6 alkyl; and R3 is C1-6 alkyl; processes for modifying a capsular saccharide with the blocking groups; saccharide-protein conjugates comprising the modified capsular saccharide; processes for making the saccharide-protein conjugates, pharmaceutical compositions comprising the modified capsular saccharides and/or saccharide-protein conjugates; and methods and uses of the same.Type: ApplicationFiled: January 11, 2008Publication date: December 23, 2010Inventors: Angela Bardotti, Alessandro Pianigiani, Francesco Berti, Paolo Costantino
-
Publication number: 20100323389Abstract: Compounds and methods are disclosed that are useful for noninvasive imaging in the near-infrared spectral range. The cyanine compounds of Formula I are presented: wherein Q is a portion of a polymethine bridge selected from the group consisting of: Also included are bioconjugates of the compounds of Formula I, methods of labeling biomolecules with the compounds, and methods of imaging.Type: ApplicationFiled: June 21, 2010Publication date: December 23, 2010Applicant: LI-COR, INC.Inventors: Xinshe Xu, Daniel R. Draney
-
Publication number: 20100310597Abstract: A method that accurately and conveniently detects a compound shown by the formula (I) in a human sample is disclosed. An antibody that reacts with the compound shown by the formula (I), but does not cross-react with the N-oxide metabolite and the desmethyl levofloxacin metabolite of the compound shown by the formula (I) is prepared using an antigen produced by binding bovine serum albumin to the compound shown by the formula (I) through the 6-position carboxyl group. Immunoassay that measures the compound shown by the formula (I) that has not been metabolized is implemented using the above antibody.Type: ApplicationFiled: December 15, 2008Publication date: December 9, 2010Inventor: Osamu Miyazaki
-
Publication number: 20100311051Abstract: The invention provides calcium-binding photoproteins which can detect light emission with a higher sensitivity. The proteins of the invention comprising the amino acid sequence of SEQ ID NO: 2 can be used for the detection and measurement of calcium ions. The proteins of the invention are useful as reporter proteins, luminescent markers, etc. The polynucleotides of the invention are useful as reporter genes, etc.Type: ApplicationFiled: May 10, 2010Publication date: December 9, 2010Inventors: Satoshi Inouye, Yuiko Sahara
-
Publication number: 20100297638Abstract: The invention relates to transmembrane protein pore for use in detecting a analyte in a sample. The pore comprises a molecular adaptor that facilitates an interaction between the pore and the analyte. The adaptor is covalently attached to the pore in an orientation that allows the analyte to be detected using the pore.Type: ApplicationFiled: October 6, 2008Publication date: November 25, 2010Applicant: ISIS INNOVATION LIMITEDInventors: John Hagan Bayley, Haichen Wu, Giovanni Maglia, Yann Astier
-
Publication number: 20100291357Abstract: The present invention relates to hydrogels and methods for producing and using the same. In particular, some embodiments of the invention relate to hydrogels and methods for patterning the same.Type: ApplicationFiled: September 18, 2008Publication date: November 18, 2010Applicant: The Regents of the University of ColoradoInventors: Brian Polizzotti, Kristi Anseth, Benjamin Fairbanks, Cole DeForest
-
Publication number: 20100286214Abstract: The present invention is directed to compounds of Formula I: or salt thereof, which are modulators of the glucocorticoid receptor. The compounds and salts of the invention are useful in the treatment of conditions mediated by glucocorticoid receptor activity.Type: ApplicationFiled: May 8, 2009Publication date: November 11, 2010Applicant: Pfizer, Inc.Inventors: Hengmiao (Henry) Cheng, Xiao Hu, Kevin D. Jerome, Mark Obukowicz, Lisa Olson, Paul V. Rucker, Ronald Keith Webber
-
Publication number: 20100267150Abstract: The present invention relates to HDM2 polypeptides and mutants thereof which are complexed with various compounds, e.g., HDM2 inhibitors.Type: ApplicationFiled: March 12, 2010Publication date: October 21, 2010Inventors: THOMAS E. HESSON, HUNG V. LE, YAO MA, VINCENT S. MADISON, ANTHONY F. MANNARINO, PAUL REICHERT, GERALD W. SHIPPS, JR., COREY O. STRICKLAND, SHAHRIAR SHANE TAREMI, YAOLIN WANG, RUMIN ZHANG, JOSE DUCA
-
Publication number: 20100267938Abstract: Compositions, methods and kits for labeling proteins and uses in reporter systems for detecting, quantifying and/or characterizing analytes.Type: ApplicationFiled: February 15, 2010Publication date: October 21, 2010Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Steven M. Menchen, Joe Y. L. Lam, Zhaochun Ma, Khairuzzaman Bashar Mullah
-
Publication number: 20100261245Abstract: The invention relates to a long-acting formulation of biopharmaceutical, more specifically an aptamer therapeutics. A branched PEGylated aptamer or a hyaluronic acid (HA) derivative of which degradation in vivo is regulated is linked by the bioconjugation with biopharmaceutical to produce the long-action formulation.Type: ApplicationFiled: April 13, 2009Publication date: October 14, 2010Inventors: Sei-Kwang HAHN, Hyun-Gu Kang, Sung-Ho Ryu, Jung-Kyu Park, Eun-Ju Oh
-
Patent number: 7807619Abstract: The present invention provides modified cycloalkyne compounds; and method of use of such compounds in modifying biomolecules. The present invention features a cycloaddition reaction that can be carried out under physiological conditions. In general, the invention involves reacting a modified cycloalkyne with an azide moiety on a target biomolecule, generating a covalently modified biomolecule. The selectivity of the reaction and its compatibility with aqueous environments provide for its application in vivo (e.g., on the cell surface or intracellularly) and in vitro (e.g., synthesis of peptides and other polymers, production of modified (e.g., labeled) amino acids).Type: GrantFiled: October 31, 2005Date of Patent: October 5, 2010Assignee: The Regents of the University of CaliforniaInventors: Carolyn R. Bertozzi, Nicholas J. Agard, Jennifer A. Prescher, Jeremy Michael Baskin
-
Publication number: 20100249372Abstract: The present invention is based on the identification of synaptic vessel glycoprotein SV2 as the BoNT/A receptor and the further identification of various BoNT/A-binding fragments of SV2. The disclosure here provides new tools for diagnosing and treating botulism.Type: ApplicationFiled: October 12, 2006Publication date: September 30, 2010Inventors: Edwin R. Chapman, Min Dong
-
Publication number: 20100249387Abstract: A process for producing coelenteramide or its analog in a high yield has been desired. The invention provides a process for producing di-O-methylcoelenteramide or its analog, which comprises reacting O-methylcoelenteramine or its analog with 4-methoxyphenylacetyl halide or its analog. The invention also provides a process for producing coelenteramide or its analog, which comprises demethylation of di-O-methylcoelenteramide or its analog.Type: ApplicationFiled: February 5, 2010Publication date: September 30, 2010Inventor: Satoshi Inouye
-
Publication number: 20100249386Abstract: The present invention relates to the field of organic chemistry and in particular to organic free radicals used as polarizing agents in the technique of Dynamic Nuclear Polarization (DNP), which involves transferring the polarization of electron spins to the nuclei of a compound whose Nuclear Magnetic Resonance (NMR) is being observed. It concerns dinitroxide-type biradical polarizing agents characterized by a rigid linkage between the nitroxide units that enables optimal orientation and distance to be maintained between the aminoxyl groups of said nitroxide units. This particular structure enables, at low temperatures and high fields, optimal transfer of polarization and optimal enhancement of NMR/MAS signals of the polarized nuclei of the compound studied.Type: ApplicationFiled: May 29, 2009Publication date: September 30, 2010Applicants: UNIVERSITE DE PROVENCE, MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Olivier OUARI, Hakim KAROUI, Francois Le MOIGNE, Paul TORDO, Robert G. Griffin, Yoh Matsuki, Thorsten Maly
-
Patent number: 7803759Abstract: A protein is efficiently nitrosylated with nitrogen monoxide by merely mixing S-nitrosoglutathione as a nitrogen monoxide donor with a protein solution containing a stabilizing agent comprising at least one compound or a combination of plural compounds selected from an N-acetylamino acid, a fatty acid, and a fatty acid salt. The method that enables efficient NO addition to a cysteine residue in un-nitrosylated protein without changing the structure of protein and hence provides NO to a living organism.Type: GrantFiled: August 7, 2007Date of Patent: September 28, 2010Assignee: Nipro CorporatonInventors: Yu Ishima, Takaaki Akaike, Masaki Otagiri
-
Patent number: 7790835Abstract: Methods for forming maleimide functionalized polymers are provided. In one such embodiment, a maleimide functionalized polymer is prepared in a method that includes a step of carrying out a reverse Diels-Alder reaction. Intermediates useful in the methods, as well as methods for preparing the intermediates, are also provided. Also provided are polymeric reagents, methods of using polymeric reagents, compounds and conjugates.Type: GrantFiled: December 3, 2004Date of Patent: September 7, 2010Assignee: Nektar TherapeuticsInventors: Samuel P. McManus, Antoni Kozlowski, Tracy L. Hutchison, Brian Bray, Xiaoming Shen
-
Publication number: 20100221176Abstract: A modular platform is provided for rapid preparation of various water-soluble prosthetic groups capable to efficiently introduce 18F into proteins with 18F labelling reagents.Type: ApplicationFiled: February 25, 2010Publication date: September 2, 2010Inventors: Herman Gill, Jan Marik, Jeff Tinianow, Simon Williams
-
Publication number: 20100210546Abstract: This invention includes compositions and methods for combination chemotherapy, particularly involving at least one chemotherapeutic agent used in combination with chlorotoxin or a derivative thereof.Type: ApplicationFiled: April 7, 2010Publication date: August 19, 2010Applicant: TRANSMOLECULAR, INC.Inventors: Vernon L. ALVAREZ, Matthew A. GONDA, Carol A. GRIMES
-
Publication number: 20100203653Abstract: The present invention relates to a protein G conjugate, which is prepared by linking an N-terminal cysteine-tagged protein G variant with an oligonucleotide via a linker. The conjugate binds in a directional manner on the surface of a biochip and biosensor, thereby providing a biochip and biosensor having improved antibody immobilization ability.Type: ApplicationFiled: May 16, 2008Publication date: August 12, 2010Inventors: Bong Hyun Chung, Yong Won Jung, Jeong Min Lee
-
Patent number: 7772179Abstract: A method for destroying harmful cells is provided, applicable in treating proliferative diseases. The cells are destroyed by a combined treatment with a chemiluminescent agent and with a ligand-photosensitizer conjugate. The chemiluminescent agent emits light on reacting with oxygen species present in situ, the conjugate binds to the cell through its ligand and is activated by the emitted light, thereby destroying the cell. The method is demonstrated on a conjugate of transferrin-hematoporphyrin, which destroys cancerous cells in the presence of luminol.Type: GrantFiled: April 20, 2006Date of Patent: August 10, 2010Assignee: Ariel-University Research and Development Company Ltd.Inventors: Michael A. Firer, Raisa Laptev
-
Publication number: 20100190775Abstract: The invention provides a pyrimidodiazepinone derivative represented by the general formula (I) [wherein n represents 1 or 2, Z represents a hydrogen atom or the like, R1 and R2 may be the same or different, and each represents a hydrogen atom or the like, A represents a bond, (CH2)m (wherein m represents an integer of 1 to 4), optionally substituted phenylene, optionally substituted pyridinediyl, or C?O, R3 represents a hydrogen atom, optionally substituted lower alkyl, or the like, and R4 represents a hydrogen atom or the like], or a pharmaceutically acceptable salt thereof or the like.Type: ApplicationFiled: June 2, 2008Publication date: July 29, 2010Applicant: Kyowa Hakko Kirin Co., LtdInventors: Nobumasa Otsubo, Yukihito Tsukumo, Kenji Uchida, Yuichi Matsumoto, Kyoichiro Iida, Hidenori Takada, Fumitake Takizawa, Hitoshi Arai, Shuko Okazaki, Takamichi Imaizumi
-
Publication number: 20100184953Abstract: Novel stable, concentrated, biologically active and ready-to-use lipid-comprising drug delivery complexes and methods for their production are described. The biological activity of the complexes produced are comparable to the formulations prepared according to the prior art admixture method and upon purification, the complexes produced by the method of this invention are 50 to 500 fold more concentrated than the complexes formed by admixture. The method described herein provides for the large scale production of lipid-comprising drug delivery systems useful for gene therapy and other applications.Type: ApplicationFiled: December 14, 2009Publication date: July 22, 2010Applicant: University of PittsburghInventors: Leaf HUANG, Xiang GAO, Frank L. SORGI
-
Patent number: 7759468Abstract: A method for preparing a site-specific peptide probe, wherein the peptide is specific to a receptor, includes modifying a marker to include a tether molecule and covalently binding the tether molecule to the peptide. The present invention also provides a labeled probe, comprising a peptide specific for a receptor and a marker. The marker is modified to include a tether molecule capable of covalently binding to the peptide. The peptide is typically derived from a bacteriophage or is a synthetic analog or derivative of the peptide. The receptor will typically be found on a surface of a bacterial cell. The method and probe of the invention are suitable for a rapid assay for a bacteria in a complex mixture.Type: GrantFiled: March 5, 2004Date of Patent: July 20, 2010Assignee: University of Kentucky Research FoundationInventors: Clair L. Hicks, Peter Anthony Crooks
-
Patent number: 7758861Abstract: The present invention discloses dye-sulfenate derivatives and their bioconjugates for dual phototherapy of tumors and other lesions. The compounds of the present invention may contain either a mixture of Type 1 and Type 2 agents or a single entity that integrates both units in the same molecules. The compounds are designed to produce both Type 1 and Type 2 phototherapeutic effect at once using dual wavelength light source that will produce singlet oxygen and free radicals at the lesion of interest.Type: GrantFiled: March 21, 2006Date of Patent: July 20, 2010Assignee: Mallinckrodt Inc.Inventors: Raghavan Rajagopalan, Samuel I. Achilefu, Joseph E. Bugaj, Richard D. Dorshow
-
Publication number: 20100167417Abstract: Reactive fluorescent dyes compositions and methods of using same are disclosed. Squaraine nucleus, Nile Red nucleus, benzodioxazole nucleus, coumarin nucleus or aza coumarin nucleus dyes are disclosed having thiol-reactive groups. Squaraine nucleus, Nile Red nucleus, benzodioxazole nucleus, coumarin nucleus or aza coumarin nucleus dyes are disclosed that exhibit a fluorescence emission of at least about 575 nm. Biosensors are disclosed having a binding protein and a squaraine nucleus, Nile Red nucleus, benzodioxazole nucleus, coumarin nucleus or aza coumarin nucleus.Type: ApplicationFiled: June 22, 2009Publication date: July 1, 2010Applicant: Becton, Dickinson and CompanyInventors: J. Bruce Pitner, Douglas B. Sherman, K. Joseph Thomas
-
Publication number: 20100160391Abstract: The present invention provides conjugates comprising a substituted aminopyridine covalently attached to an organic molecule via an amide bond. Such conjugates find utility as substrates for amide hydrolases, where the substituted aminopyridine acts as a fluorescent reporter of amide hydrolase activity. As a result, the conjugates described herein can advantageously be used in assays to detect amide hydrolase activity based upon measuring the fluorescence of a substituted aminopyridine that is released after amide hydrolysis. The conjugates of the present invention are also particularly useful in screening assays, which enable the identification of inhibitory molecules for amide hydrolases and other enzymes. The identified amide hydrolase inhibitors can be used in the treatment of a variety of diseases and disorders associated with aberrant amide hydrolase activity.Type: ApplicationFiled: July 9, 2007Publication date: June 24, 2010Inventors: Bruce D. Hammock, Huazhang Huang, Kosuke Nishi
-
Publication number: 20100136567Abstract: The invention provides a novel class of cyanine dyes that are functionalized with a linker moiety that facilitates their conjugation to other species. Also provided are conjugates of the dyes, methods of using the dyes and their conjugates and kits including the dyes and their conjugates.Type: ApplicationFiled: January 5, 2010Publication date: June 3, 2010Applicant: Biosearch Technologies, Inc.Inventors: Tim Carter, Mark Reddington
-
Patent number: 7718607Abstract: A protein is efficiently nitrosylated with nitrogen monoxide by merely mixing S-nitrosoglutathione as a nitrogen monoxide donor with a protein solution containing a stabilizing agent comprising at least one compound or a combination of plural compounds selected from an N-acetylamino acid, a fatty acid, and a fatty acid salt. The method that enables efficient NO addition to a cysteine residue in un-nitrosylated protein without changing the structure of protein and hence provides NO to a living organism.Type: GrantFiled: July 11, 2008Date of Patent: May 18, 2010Assignee: NIPRO CorporationInventors: Yu Ishima, Takaaki Akaike, Masaki Otagiri
-
Publication number: 20100121034Abstract: The invention relates to Fmoc (9-fluorenyl-methoxycarbonyl)-based polymeric conjugates. These conjugates are useful for extending the in-vivo circulation of protein and peptide drugs.Type: ApplicationFiled: January 15, 2010Publication date: May 13, 2010Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.Inventors: Peter Turecek, Juergen Siekmann
-
Publication number: 20100111856Abstract: Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab) are conjugated with one or more zirconium complex (Z) labels through a linker (L) to form cysteine engineered zirconium-labeled antibody conjugates having Formula I: Ab-(L-Z)p??I where p is 1 to 4. Imaging methods and diagnostic uses for zirconium-radiolabeled, cysteine engineered antibody conjugate compositions are disclosed.Type: ApplicationFiled: November 5, 2009Publication date: May 6, 2010Inventors: Herman Gill, Jagath R. Junutula, Henry B. Lowman, Jan Marik, Jeff Tinianow, Simon Williams
-
Publication number: 20100086568Abstract: The invention relates to a process for modifying allergens to enhance their suitability in immunotherapy. The invention further relates to the modified allergens and pharmaceutical compositions thereof, as well as to their use in immunotherapy.Type: ApplicationFiled: July 14, 2009Publication date: April 8, 2010Inventors: Stefan Johan KOPPELMAN, Robertus Henricus Joannes Alfonsus Van Den Hout, Henriëtte Emilie Sleijster-Selis, Dionisius Marinus Antonius Maria Luijkx
-
Publication number: 20100069607Abstract: A glycopeptide of the formula S-L-X—P, wherein: S is selected from an optionally protected monosaccharide, an optionally protected polysaccharide, a polyalkylene oxide chain and a group of the formula II, wherein R1 and R3 are independently selected from H or Ac, R4 is Ac, and R2 is a group of formula IV, wherein R7 and R8 are each independently selected from an optionally protected monosaccharide and an optionally protected polysaccharide, A, B, C and D are each independently 1 or 2, and m is 1 to 5; -L- is a moiety of the formula III wherein R5 and R6 are independently selected from H and Me and n is 1 to 3; and P is a peptide chain containing at least one amino acid having on its side chain the atom X, wherein X is an oxygen, a sulphur atom or a —CH2— moiety.Type: ApplicationFiled: June 29, 2007Publication date: March 18, 2010Applicant: UCL BUSINESS PLCInventors: Derek MacMillan, Javier Blanc
-
Publication number: 20100036102Abstract: This invention relates to a group of novel chelating agents, novel chelates, biomolecules labeled with said chelates or chelating agents as well as solid supports conjugated with said chelates, chelating agents or labeled biomolecules. Especially the invention relates to novel chelating agents useful in solid phase synthesis of oligonucleotides or oligopeptides and the oligonucleotides and oligopeptides so obtained.Type: ApplicationFiled: October 16, 2009Publication date: February 11, 2010Applicant: WALLAC OYInventors: Jari HOVINEN, Veli-Matti Mukkala, Harri Hakala, Jari Peuralahti
-
Publication number: 20100029906Abstract: The present invention relates to new synthetic receptors. More particularly, the present invention relates to the use of the synthetic receptors for delivering a protein, peptide, drug, prodrug, lipid, nucleic acid, carbohydrate or small molecule into a target cell via receptor-mediated endocytosis. According to the invention, novel synthetic mimics of cell surface receptors have been designed and methods for use of the same are disclosed.Type: ApplicationFiled: December 16, 2008Publication date: February 4, 2010Applicant: THE PENN STATE RESEARCH FOUNDATIONInventor: Blake R. Peterson
-
Publication number: 20100022456Abstract: The patent application relates to antagonistic dimers of prolactin molecules and their use in treating cancer.Type: ApplicationFiled: December 20, 2007Publication date: January 28, 2010Applicant: Novo Nordisk A/SInventors: Leif Christensen, Leif Norskov-Lauritsen, Lone Risegaard, Nils Billestrup, Svetlana Tarabykina
-
Publication number: 20100003735Abstract: A linker system is provided where a small molecule reactive group, e.g., an activity based probe which binds to certain enzymes at the active site, is linked through an aryl diazo linker to an affinity molecule such as biotin. The reactive group may comprise a number of functionalities known to react with a specific target to be studied. This enables the probe to be exposed to analytes, such as proteins and bind specifically to them to form a complex having an affinity molecule allowing immobilization of the bound analyte on an affinity column or other support, e.g. with streptavidin. Then, the linker is cleaved without causing removal of the affinity group or dissociation of the probe from the analyte. The linker is cleaved under mild reducing conditions, e.g., dithionite. The probe is synthesized along with the linker on a solid support.Type: ApplicationFiled: August 1, 2007Publication date: January 7, 2010Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Matthew S. Bogyo, Steven H.L. Verhelst, Marko Fonovic
-
Publication number: 20100004316Abstract: Described herein are multifunctional compounds useful as devices for the delivery of nucleic acids to cells. Also described herein are methods for using the multifunctional compounds.Type: ApplicationFiled: September 27, 2007Publication date: January 7, 2010Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Zheng-Rong Lu, Xu-Li Wang
-
Publication number: 20090324501Abstract: The present invention relates to a hypoallergenic protein consisting of at least one hypoallergenic molecule derived from an allergen, which is fused or conjugated to at least one second non-allergenic protein or fragment thereof.Type: ApplicationFiled: June 11, 2007Publication date: December 31, 2009Applicant: Biomay AGInventors: Rudolf Valenta, Margarete Focke-Tejkl, Birgit Linhart, Susanne Vrtala, Peter Valent, Renat Reininger, Susanne Spitzauer, Ines Swoboda, Marianne Van Hage, Hans Grönlund, Johanna Tinhofer, Kerstin Westritschnig, Theresia Popow-Kraupp
-
Publication number: 20090314990Abstract: Triphenylamine derivatives useful as fluorophores in biology, in particular for two-photon microscopy; and compositions comprising these derivatives, to the use of these compositions and of the derivatives themselves for labelling biological molecules (or “biomolecules”) such as nucleic acids, oligonucleotides, proteins, polypeptides, plasmids, and the like, for their examination in particular by two-photon microscopy, and to biomolecules labelled with the said derivatives.Type: ApplicationFiled: November 9, 2007Publication date: December 24, 2009Inventors: Clémence Allain, Fabrice Charra, Céline Fiorini-Debuisschert, Rémy Lartia, Marie-Paule Teulade-Fichou
-
Patent number: 7632929Abstract: The invention generally relates to hapten compounds comprising either (+) methamphetamine or (+) amphetamine conjugated to a linker. Generally speaking, hapten compounds of the invention may be used to elicit an immune response to one or more of (+) methamphetamine, (+) amphetamine, or (+) MDMA.Type: GrantFiled: April 9, 2007Date of Patent: December 15, 2009Assignee: The Board of Trustees of the University of ArkansasInventors: Samuel M. Owens, Frank Ivy Carroll, Philip Abraham
-
Publication number: 20090305410Abstract: The present invention relates to fluorescent dyes in general. The present invention provides a wide range of fluorescent dyes and kits containing the same, which are applicable for labeling a variety of biomolecules, cells and microorganisms. The present invention also provides various methods of using the fluorescent dyes for research and development, forensic identification, environmental studies, diagnosis, prognosis, and/or treatment of disease conditions.Type: ApplicationFiled: December 12, 2008Publication date: December 10, 2009Applicant: Biotium, Inc.Inventors: Fei Mao, Wai-Yee Leung, Ching-Ying Cheung, Hye Eun Hoover
-
Publication number: 20090305998Abstract: The invention relates to HSP90 inhibiting compounds consisting of the formula: wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.Type: ApplicationFiled: January 30, 2009Publication date: December 10, 2009Applicant: Takeda Pharmaceutical Company LimitedInventors: Young K. Chen, Erick Co, Prasuna Guntupalli, John D. Lawson, Wolfgang Reinhard Ludwig Notz, Jeffrey A. Stafford, Huong-Thu Ton-Nu
-
Patent number: 7622552Abstract: A method of ligating two or more molecules, for example, peptides to peptides or peptides to labels is provided. The method may comprise the steps: a) providing a first oligopeptide having a reactive moiety, which is a hydrazine moiety, a hydrazide moiety or an amino-óxy moiety b) providing a second oligopeptide having an activated ester moiety, c)allowing the reactive moiety of the first oligopeptide to react with the activated ester moiety of the second oligopeptide to form an oligopeptide product, in which the first and second oligopeptides are linked via a linking moiety having Formula I, II or III. The second oligopeptide may preferably be generated by thiol reagent induced cleavage of an intein fusion protein. The invention further provides labelling and ligation methods in which protein hydrazides are ligated by reaction of the hydrazide moiety with an aldehyde functionality or a ketone functionality.Type: GrantFiled: August 5, 2004Date of Patent: November 24, 2009Assignee: Almac Sciences (Scotland) LimitedInventor: Graham Cotton
-
Publication number: 20090286808Abstract: The present invention provides compositions and methods useful in the treatment and/or prevention of ophthalmic conditions and diseases, such as retinitis pigmentosa, that are dependent upon or related to misfolded opsin proteins in vivo. In addition, screening assays for agents useful in such treatment methods are described.Type: ApplicationFiled: January 21, 2009Publication date: November 19, 2009Applicant: University of Florida Research Foundation, Inc.Inventors: Shalesh Kaushal, Syed M. Noorwez, David A. Ostrov
-
Publication number: 20090281287Abstract: The present invention provides for IL-17 receptor like polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, agonists and antagonists (including selective binding agents), and methods for producing IL-17 receptor like polypeptides. Also provided for are methods for treatment, diagnosis, amelioration, or prevention of diseases with IL-17 receptor like polypeptides.Type: ApplicationFiled: June 3, 2009Publication date: November 12, 2009Applicant: Amgen Inc.Inventors: Eugene Medlock, Richard Yeh, Scott M. Silbiger, Gary S. Elliott, Hung Q. Nguyen, Shuqian Jing
-
Publication number: 20090270598Abstract: The invention provides amphiphiles for manipulating membrane proteins. The amphiphiles can feature carbohydrate-derived hydrophilic groups and branchpoints in the hydrophilic moiety and/or in a lipophilic moiety. Such amphiphiles are useful as detergents for solubilization and stabilization of membrane proteins, including photosynthetic protein superassemblies obtained from bacterial membranes.Type: ApplicationFiled: April 8, 2009Publication date: October 29, 2009Applicant: WARF - Wisconsin Alumni Research FoundationInventors: Samuel Helmer Gellman, Pil Seok Chae, Philip D. Laible, Marc J. Wander
-
Publication number: 20090264455Abstract: Provided herein are compounds that bind to androgen receptors and/or modulate activity of androgen receptors, and to methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.Type: ApplicationFiled: June 12, 2006Publication date: October 22, 2009Applicant: LIGAND PHARMACEUTICALS INCORPORATEDInventors: Bijan Pedram, Cornelis Arjan Van Oeveren, Lin Zhi, Shuo Zhao, Yixing Shen